AXSM Stock Axsome Therapeutics, Inc.

$129.36
1d-4.66%5d-8.7%1m-17.24%ytd-29.17%
At close · Nov 20, 4:00 PM ET
After hours $129.36 +0% · Nov 20, 4:52 PM ET
52w low $1235% of range$260.19 52w high
Price

Today’s call · AXSM

All live ideas →

5 of 6 technical checks lean bearish

AXSM is in a downtrend, momentum firm. $150 is the level overhead; $125 the first support below.

No open idea.From $129.36 the reward-to-risk to $125 against $150 is 0.2 — below the 3:1 bar.
What would create one:
  • A close below $125 on rising volume (breakdown).
  • A bounce to $150 that fails (entry near resistance).
Alert me at a level

The brief

Price vs 50-day · belowPrice vs 200-day · below50d vs 200d avg · belowMACD · bullishRSI momentum · 335-day tape · -8.7%
signalAXSM’s 50-day average is below the 200-day — long-term trend alignment is bearish.
All readings
TrendDowntrend · below 50-day & below 200-day
MomentumRSI 32.9 · MACD bullish
Trend strengthADX 33.5 · strong trend
Location-21.0% vs 50-day MA
52-week range-49% from high · +0% from low
VolatilityATR 6.5 · ~5.0%/day
RSI 14
32.9
MACD
-7.78
ADX 14
33.5
ATR 14
6.50
SMA 50
$163.75
SMA 200
$195.79

Levels that matter

$150round+16.0%
$151.79swing zone · 2×+17.3%
$163.75sma 50+26.6%
$125round−3.4%
$100round−22.7%

Compare with…

Analyst overview · Nov 15

Axsome Therapeutics (AXSM) stock analysis, November 15, 2026: bearish outlook amid weakening momentum

Axsome Therapeutics closed at $141.69 on November 13, a level well below its 52‑week low of $129.80 and far beneath the 50‑day simple moving average of $171.45. The daily trend follows a weekly downtrend, and the stock has lagged both the S&P 500 and the health‑care sector ETF XLV over the past 50 days. With a high conviction bearish stance for the next two to six weeks, the balance of evidence points to further downside, though the math does not yet justify a three‑to‑one risk‑reward for a breakout trade.

Why it matters

The recent price action reflects a market that has already priced in the steep correction from the October 12 peak of $166.00, a drop of roughly 14.6%. The stock’s 5‑day gain of 7.0% is an outlier in a broader context of underperformance: over the same period AXSM lagged the S&P 500 by 16.2% and the XLV sector ETF by 24.0%. This divergence suggests that the rally was driven more by short‑term technical bounce than by any fundamental catalyst.

Fundamentally, the company faces a challenging environment. Analysts remain overwhelmingly optimistic, with a consensus of strong‑buy and a mean price target of $265.86, yet the current price sits 46.7% below that mean. The gap between consensus expectations and market reality underscores a disconnect that the market has not yet resolved. The sector backdrop is supportive—XLV is up 2.2% over five days and 8.6% over one month—but AXSM’s relative weakness indicates company‑specific concerns dominate the narrative.

The debate among market participants centers on whether the recent bounce is a genuine reversal or a fleeting technical rebound. Proponents of a turnaround point to the 5‑day rally and the fact that the stock remains above the 52‑week low, arguing that the price is finding a floor near $129.80. Critics counter that the daily trend remains aligned with the weekly downtrend, the RSI sits at 40.8 (still below neutral), and volume is down 14.8% versus its 20‑day average, indicating waning buying interest. Both sides agree that the next earnings report on November 2 will be a key catalyst, but the consensus view is that earnings are unlikely to close the valuation gap.

Valuation remains a stark outlier. The mean target of $265.86 implies a 46.7% upside from the current price, yet the stock’s long‑term trend is down, with price below both its 40‑week average and the 200‑day SMA of $197.05. The disparity between analyst optimism and market pricing suggests that the consensus may be overly sanguine, or that the market is demanding a substantial catalyst before it aligns with those targets.

What the evidence says

On the long‑term horizon, the thesis that AXSM is in a downtrend remains intact. The price is below its 40‑week average, the 52‑week low is only 9.2% away, and the 200‑day SMA sits at $197.05, well above current levels. The stock is in the “down” phase of its cycle, with the weekly trend confirming the bearish bias. No new fundamental data have emerged to overturn this view, and the recent 5‑day rally does not alter the longer‑term structural weakness.

Looking ahead to the next two to six weeks, the balance of evidence leans negative with high conviction. The assessment notes three of four conviction points: the daily trend mirrors the weekly downtrend, the stock lags the S&P 500 by 16.2% over 50 days, and it lags XLV by 24.0% over the same period. The breakout math points to a downside breakout if the price closes below the 52‑week low of $129.80, with a stop set at $152.09 (rounded $150 plus a quarter of the 14‑day ATR of $8.38). Targets are $125 and $100, offering reward‑to‑risk ratios of 0.2 and 1.3 respectively. The math does not meet a 3‑to‑1 ratio; a price of roughly $115 would be needed to achieve that threshold, which is below the first target.

The strongest case against a bearish reading would be a sustained close above the 50‑day SMA of $171.45, which would signal a reversal of the weekly trend. However, the stock is currently 40% below that level, and volume is contracting, making such a move unlikely without a major catalyst.

Levels that matter

The structure holds below $150, a round level where sellers have historically stepped in on rallies. The weekly trend is down, and $150 has acted as a resistance zone in recent weeks, reinforcing its significance. The trend would be considered ended if the price were to close above $171.45, the 50‑day SMA, on a weekly basis; that would indicate a shift in the weekly bias.

The breakout level is the 52‑week low of $129.80. A daily close below that level would trigger the downside math, with a stop at $152.09. The first target is $125, a round level just below the breakout point, offering a modest reward‑to‑risk of 0.2. The second target at $100 provides a more attractive reward‑to‑risk of 1.3 but still falls short of the 3‑to‑1 benchmark. To achieve a 3‑to‑1 ratio, the price would need to move to roughly $115, which is not captured by the current target set.

What would change the picture

A weekly close above $171.45, the 50‑day SMA, would alter the picture by ending the downtrend and opening the possibility of a new upside bias. The non‑price factor that could also shift the narrative is a materially better‑than‑expected earnings report on November 2, particularly if it includes new data that narrows the gap to analyst price targets.

What to watch

  • November 2 earnings – focus on revenue growth, pipeline milestones, and any guidance that narrows the valuation gap.
  • Sector developments – watch for FDA approvals or setbacks in the broader biotech space that could move XLV and, by extension, AXSM.
  • Valuation pressure – the consensus strong‑buy rating and mean target of $265.86 remain far above the current price, highlighting the disconnect that could be resolved only by a significant catalyst.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.